Heat therapy plus standard care for advanced rectal cancer
Part of Cancer, Digestive system, Injuries & trauma clinical trials.
This trial tests whether adding modulated electro-hyperthermia (a gentle heat treatment) to standard therapy (radiation and chemotherapy) before surgery helps control locally advanced rectal cancer. It is for people whose cancer has not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 20 years or older.
- You have a specific type of rectal cancer (adenocarcinoma) that is locally advanced (stages cT3 or cT4 with some lymph node involvement, but no spread to other organs).
- You are healthy enough to undergo standard treatment, including radiation (25-30 sessions) and chemotherapy (capecitabine or fluorouracil, followed by 4-6 months of modified FOLFOX-6 or CAPEOX).
- You do not have active infections, HIV, untreated thyroid disease, Crohn's disease, ulcerative colitis, or other uncontrolled autoimmune diseases.
- You are not pregnant, breastfeeding, or dependent on alcohol or drugs in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of delivering radiation therapy for rectal cancer before surgery. It aims to see if adapting the radiation based on how the tumor shrinks can be more effective and safer than standard treatment.
This trial tests if adding heat therapy (hyperthermia) to standard chemotherapy and radiation helps treat rectal cancer that has high-risk features. Heat therapy is thought to make cancer cells more sensitive to treatment.
This trial tests whether adding heat therapy (hyperthermia) to a second round of radiation can help treat cancer that has come back in the same area after previous radiation. It may be an option if your tumor is in a part of the body that can be safely heated, like the belly or limbs.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a new approach for people with high-risk rectal cancer that has not spread. It combines short-course radiation with a four-drug chemotherapy and an immunotherapy drug before surgery, aiming to shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.